IPCIQ (IntelliPharmaCeutics International) Institutional Ownership: 0.63% (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPCIQ IntelliPharmaCeutics International Inc IPCIQ
16 GF Score
Price $0.15
View Full Analysis

What is IntelliPharmaCeutics International Institutional Ownership?

IntelliPharmaCeutics International IPCIQ -100.00% 16 Institutional Ownership is 0.63% as of Aug. 30, 2026. GuruFocus rates IPCIQ with a GF Score™ of 16/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, IntelliPharmaCeutics International's institutional ownership is 0.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, IntelliPharmaCeutics International's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, IntelliPharmaCeutics International's Float Percentage Of Total Shares Outstanding is 0.00%.

IntelliPharmaCeutics International Institutional Ownership Historical Data

* Premium members only.

The historical data trend for IntelliPharmaCeutics International's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Institutional Ownership Chart

IntelliPharmaCeutics International Historical Data

The historical data trend for IntelliPharmaCeutics International can be seen below:

2019-02-28 2020-03-31 2020-04-30 2020-05-31 2020-06-30 2020-07-31 2020-08-31 2020-09-30 2020-10-31 2020-11-30
Institutional Ownership 0.82 0.70 0.70 0.70 0.65 0.63 0.63 0.63 0.63 0.63
IPCIQ
16GF Score
IntelliPharmaCeutics International Inc IPCIQ
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IntelliPharmaCeutics International Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.63% mean?
IntelliPharmaCeutics International (IPCIQ) has a Institutional Ownership of 0.63% as of Aug. 30, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IntelliPharmaCeutics International and its competitors.
Is IntelliPharmaCeutics International's Institutional Ownership too high?
IntelliPharmaCeutics International's current Institutional Ownership is 0.63%. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's Institutional Ownership compare to CHRO and KTTA?
IntelliPharmaCeutics International's Institutional Ownership of 0.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on IntelliPharmaCeutics International and its competitors. IntelliPharmaCeutics International's current Institutional Ownership is 0.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current Institutional Ownership of 0.63%. The current Institutional Ownership is 0.63%. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current Institutional Ownership is 0.63% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IntelliPharmaCeutics International Business Description

Address 30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score

Get the complete analysis for IPCIQ

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price